Compare Quest Diagnostics Inc (DGX) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hims and Hers Health Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Hims and Hers Health Inc trades at $35.25 (market cap $8.14B). The key difference: Quest Diagnostics Inc is far larger — about 2.8× Hims and Hers Health Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| DGX | HIMS | |
|---|---|---|
Market Cap | $22.80B | $8.14B |
Sector | Health | Health |
52-Week High | $216.02 | $66.18 |
52-Week Low | $166.42 | $14.52 |
Enterprise Value | $28.82B | $8.52B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Hims & Hers Health trades at $34.38, showing no change in the last session. The stock exhibits a bullish technical setup with moving averages supporting upward momentum, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing expectations, but revenue growth remains positive. Analyst sentiment is divided with a 35% buy rating, and the consensus price target is $33.57. News highlights include expansion in weight-loss treatments and a new JPMorgan receivables facility.
The outlook for HIMS is cautiously optimistic, driven by growth in telehealth and weight-loss segments, but high valuation multiples and recent net income declines pose risks. Investment opportunity lies in market expansion and subscriber growth, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
